The histone modifier KAT2A presents a selective target in a subset of well-differentiated microsatellite-stable colorectal cancers
V. Kufrin, A. Seiler, S. Brilloff…·A. A. Wurm
This study identifies KAT2A as a therapeutic target in a subset of well-differentiated, microsatellite-stable colorectal cancers by showing its dependency and functional consequences.